Search

1244447
1240861
1230819
1195994
393884
Final results from M72 AS01E TB Vaccine Trial
The final results from the M72AS01E TB vaccine study have been published in the New England Journal of Medicine. The vaccine demonstrated a 50% efficacy rate in reducing the incidence of lung TB disease in HIV-negative adults, already infected with...
Beat TB drama production
Beat TB, a Welcome Trust funded street theater production which raised awareness about tuberculosis (TB) and vaccine research understanding amongst the broader public of the Worcester area. during 2016.
2018 Tb under the Spotlight Science Engagement
The “TB Under the Spotlight Science Engagement” programme was conceptualised and presented by South African Tuberculosis Vaccine Initiative (SATVI) with scientists from the Division of Molecular Biology and Human Genetics at Stellenbosch University...
Biomarker discovery offers hope for new TB vaccine development
A team of scientists from the University of Cape Town, Oxford University and the London School of Hygiene & Tropical Medicine have made a discovery that reveals how we can improve development of more effective vaccines against tuberculosis.
Community Engagement
Carina's Choice: SATVI collaborated with UCT Drama Department and Worcester Secondary School in developing this play which was performed by learners from Worcester Secondary School at 8 local high schools reaching approximately 8 000 adolescents in...

News

Friday, 10 April 2020
22 February 2020 Research: Immune correlates of tuberculosis disease and risk translate across species.

SATVI researcher Professor Tom Scriba and Stanley Kimbung Mbandi have co-authored an article titled "Immune correlates of tuberculosis disease and risk translate across species" appearing in the Science Translational Medicine journal.

Publication Date:
Sun, 23 Feb 2020 - 11:30
21 January 2020: Latest Research: Headway made towards biosignatures for tuberculosis incipient

Professor Tom Scriba and Dr Simon Mendelsohn have published a journal article titled: "Making headway towards biosignatures for incipient tuberculosis" appearing in the Lancet Respiratory Medicine. 

Publication Date:
Tue, 21 Jan 2020 - 15:00
2 December 2019: EDCTP funded clinical trial testing new tuberculosis vaccine initiates vaccinations

The Prevention of Recurrence (POR) Consortium has been awarded a substantial grant from the European & Developing Countries Clinical Trial Partnership (EDCTP) which will support a clinical trial in South Africa and Tanzania of a new and promising tuberculosis (TB) vaccine candidate H56:IC31, developed by the Statens Serum Institute (SSI). 

Publication Date:
Wed, 18 Dec 2019 - 08:45
22 November 2019 Research Preferred product characteristics for therapeutive vaccines

Professor Mark Hatherill has co-authored a journal article titled: "Preferred product characteristics for therapeutic vaccines to improve tuberculosis treatment outcomes: Key considerations from World Health Organisation consultations" appearing in the Vaccine journal.

Publication Date:
Fri, 22 Nov 2019 - 13:45

Pages